艾司奥美拉唑联合莫沙必利治疗反流性食管炎患者的应用效果观察

Effect of esomeprazole combined with mosapride in the treatment of patients with reflux esophagitis

目的:探讨反流性食管炎患者应用艾司奥美拉唑联合莫沙必利治疗的效果。方法:选取2019年5月—2020年6月于本院就诊的92例反流性食管炎(RE)患者,采用随机数字表法分为两组,每组各46例。对照组口服莫沙必利治疗,10 mg/次,3次/d;同时口服奥美拉唑,20 mg/次,2次/d。观察组在对照组基础上口服艾司奥美拉唑,40 mg/次,2次/d。两组均连续治疗4周。对比两组临床效果、症状改善情况、胃肠激素水平[胃动素(MTL)和血浆胃泌素(GAS)]及不良反应情况。结果:观察组临床总有效率高于对照组,有统计学差异(P<0.05);两组治疗前烧心、反酸评分及MTL、GAS水平比较,无统计学差异(P>0.05);两组治疗后烧心、反酸评分均较治疗前降低,且观察组低于对照组,治疗后MTL、GAS水平均较治疗前升高,且观察组高于对照组,有统计学差异(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论:RE患者应用艾司奥美拉唑联合莫沙必利治疗能促进胃肠蠕动,改善患者临床症状,安全可靠,利于患者预后。

Objective:To investigate the effect of esomeprazole combined with mosapride in the treatment of patients with reflux esophagitis.Methods:A total of 92 patients with reflux esophagitis(RE)admitted to our hospital from May 2019 to June 2020 were selected and divided into two groups by random number table method,with 46 cases in each group.The control group was treated with mosapride orally,10 mg/time,3 times/day.At the same time,omeprazole was taken orally,20 mg/time,twice a day.The observation group was treated with mosapride orally with the same dosage as the control group,and esomeprazole was taken orally,40 mg/time,twice a day.Both groups were treated continuously for four weeks.The clinical effect,symptom improvement,gastrointestinal hormone levels,including motilin(MTL)and plasma gastrin(GAS),and adverse reactions were compared between the two groups.Results:The total clinical effective rate in the observation group was higher than that in the control group,with a statistical difference(P<0.05).Before treatment,there were no significant differences in heartburn,acid reflux scores,and MTL and GAS levels between the two groups(P>0.05).After treatment,the scores of heartburn and acid reflux in both groups were lower than before treatment,and the observation group was lower than the control group.Moreover,after treatment,the levels of MTL and GAS were higher than before treatment,and the observation group was higher than the control group,with statistical differences(P<0.05).There was no significant difference in ADR between the two groups(P>0.05).Conclusion:In RE patients,esomeprazole combined with mosapride can promote gastrointestinal peristalsis and improve clinical symptoms,which is safe and reliable and can be beneficial to the prognosis of patients.